Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor

Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Arun Lakshmanan, Ken'ichi Yamaguchi, Meilei Ma, Kenji Suzuki, Masaki Nagata, Ritsuo Takagi, Makoto Kodama, Kenichi Watanabe

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Angiotensin-converting enzyme 2 (ACE-2) is a membrane-associated carboxy-peptidase catalyzes the conversion of the vasoconstrictor angiotensin (ANG)-II to the vasodilatory peptide ANG 1-7. In view of the expanding axis of the renin angiotensin system, we have investigated the cardioprotective effects of olmesartan (10. mg/kg/day) in experimental autoimmune myocarditis. Olmesartan treatment effectively suppressed the myocardial protein expressions of inflammatory markers in comparison to the vehicle-treated rats. However, the protein and mRNA levels of ACE-2 and ANG 1-7, and its receptor Mas were upregulated in olmesartan treated group compared to vehicle-treated rats. Olmesartan medoxomil treatment significantly decreased the expression levels of phospho-p38 mitogen-activated protein kinase (MAPK), phospho-JNK, phospho-ERK and phospho-(MAPK) activated protein kinase-2 than with those of vehicle-treated rats. Moreover, vehicle-treated rats were shown to be up-regulated protein expressions of NADPH oxidase subunits (p47phox, p67phox and Nox-4), myocardial apoptotic markers and endoplasmic reticulum stress markers in comparison to those of normal and all these effects are expectedly down-regulated by an olmesartan. In addition, attenuated protein levels of phosphatidylinositol-3-kinase (PI3K) and phospho-Akt in the vehicle-treated EAM rats were prevented by olmesartan treatment. Our results suggest that beneficial effects of olmesartan treatment was more effective therapy in combating the inflammation, oxidative stress, apoptosis and signaling pathways associated with heart failure at least in part via the modulation of ANG 1-7 mas receptor.

Original languageEnglish
Pages (from-to)208-219
Number of pages12
JournalMolecular and Cellular Endocrinology
Volume351
Issue number2
DOIs
Publication statusPublished - 4 Apr 2012
Externally publishedYes

Fingerprint

Myocarditis
Rats
Heart Failure
Modulation
Proteins
Phosphatidylinositol 3-Kinase
Endoplasmic Reticulum Stress
Oxidative stress
NADPH Oxidase
Angiotensins
Vasoconstrictor Agents
p38 Mitogen-Activated Protein Kinases
Renin-Angiotensin System
Mitogen-Activated Protein Kinases
Renin
Angiotensin II
Protein Kinases
olmesartan
angiotensin I (1-7)
Oxidative Stress

Keywords

  • Angiotensin 1-7
  • Angiotensin-converting enzyme-2
  • Angiotensin-II
  • Experimental autoimmune myocarditis
  • MAPK signaling pathways
  • Olmesartan

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Cite this

Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. / Sukumaran, Vijayakumar; Veeraveedu, Punniyakoti T.; Gurusamy, Narasimman; Lakshmanan, Arun; Yamaguchi, Ken'ichi; Ma, Meilei; Suzuki, Kenji; Nagata, Masaki; Takagi, Ritsuo; Kodama, Makoto; Watanabe, Kenichi.

In: Molecular and Cellular Endocrinology, Vol. 351, No. 2, 04.04.2012, p. 208-219.

Research output: Contribution to journalArticle

Sukumaran, V, Veeraveedu, PT, Gurusamy, N, Lakshmanan, A, Yamaguchi, K, Ma, M, Suzuki, K, Nagata, M, Takagi, R, Kodama, M & Watanabe, K 2012, 'Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor', Molecular and Cellular Endocrinology, vol. 351, no. 2, pp. 208-219. https://doi.org/10.1016/j.mce.2011.12.010
Sukumaran, Vijayakumar ; Veeraveedu, Punniyakoti T. ; Gurusamy, Narasimman ; Lakshmanan, Arun ; Yamaguchi, Ken'ichi ; Ma, Meilei ; Suzuki, Kenji ; Nagata, Masaki ; Takagi, Ritsuo ; Kodama, Makoto ; Watanabe, Kenichi. / Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. In: Molecular and Cellular Endocrinology. 2012 ; Vol. 351, No. 2. pp. 208-219.
@article{0dcfa14a37ff4607b6dbd6670bc7ecdb,
title = "Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor",
abstract = "Angiotensin-converting enzyme 2 (ACE-2) is a membrane-associated carboxy-peptidase catalyzes the conversion of the vasoconstrictor angiotensin (ANG)-II to the vasodilatory peptide ANG 1-7. In view of the expanding axis of the renin angiotensin system, we have investigated the cardioprotective effects of olmesartan (10. mg/kg/day) in experimental autoimmune myocarditis. Olmesartan treatment effectively suppressed the myocardial protein expressions of inflammatory markers in comparison to the vehicle-treated rats. However, the protein and mRNA levels of ACE-2 and ANG 1-7, and its receptor Mas were upregulated in olmesartan treated group compared to vehicle-treated rats. Olmesartan medoxomil treatment significantly decreased the expression levels of phospho-p38 mitogen-activated protein kinase (MAPK), phospho-JNK, phospho-ERK and phospho-(MAPK) activated protein kinase-2 than with those of vehicle-treated rats. Moreover, vehicle-treated rats were shown to be up-regulated protein expressions of NADPH oxidase subunits (p47phox, p67phox and Nox-4), myocardial apoptotic markers and endoplasmic reticulum stress markers in comparison to those of normal and all these effects are expectedly down-regulated by an olmesartan. In addition, attenuated protein levels of phosphatidylinositol-3-kinase (PI3K) and phospho-Akt in the vehicle-treated EAM rats were prevented by olmesartan treatment. Our results suggest that beneficial effects of olmesartan treatment was more effective therapy in combating the inflammation, oxidative stress, apoptosis and signaling pathways associated with heart failure at least in part via the modulation of ANG 1-7 mas receptor.",
keywords = "Angiotensin 1-7, Angiotensin-converting enzyme-2, Angiotensin-II, Experimental autoimmune myocarditis, MAPK signaling pathways, Olmesartan",
author = "Vijayakumar Sukumaran and Veeraveedu, {Punniyakoti T.} and Narasimman Gurusamy and Arun Lakshmanan and Ken'ichi Yamaguchi and Meilei Ma and Kenji Suzuki and Masaki Nagata and Ritsuo Takagi and Makoto Kodama and Kenichi Watanabe",
year = "2012",
month = "4",
day = "4",
doi = "10.1016/j.mce.2011.12.010",
language = "English",
volume = "351",
pages = "208--219",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor

AU - Sukumaran, Vijayakumar

AU - Veeraveedu, Punniyakoti T.

AU - Gurusamy, Narasimman

AU - Lakshmanan, Arun

AU - Yamaguchi, Ken'ichi

AU - Ma, Meilei

AU - Suzuki, Kenji

AU - Nagata, Masaki

AU - Takagi, Ritsuo

AU - Kodama, Makoto

AU - Watanabe, Kenichi

PY - 2012/4/4

Y1 - 2012/4/4

N2 - Angiotensin-converting enzyme 2 (ACE-2) is a membrane-associated carboxy-peptidase catalyzes the conversion of the vasoconstrictor angiotensin (ANG)-II to the vasodilatory peptide ANG 1-7. In view of the expanding axis of the renin angiotensin system, we have investigated the cardioprotective effects of olmesartan (10. mg/kg/day) in experimental autoimmune myocarditis. Olmesartan treatment effectively suppressed the myocardial protein expressions of inflammatory markers in comparison to the vehicle-treated rats. However, the protein and mRNA levels of ACE-2 and ANG 1-7, and its receptor Mas were upregulated in olmesartan treated group compared to vehicle-treated rats. Olmesartan medoxomil treatment significantly decreased the expression levels of phospho-p38 mitogen-activated protein kinase (MAPK), phospho-JNK, phospho-ERK and phospho-(MAPK) activated protein kinase-2 than with those of vehicle-treated rats. Moreover, vehicle-treated rats were shown to be up-regulated protein expressions of NADPH oxidase subunits (p47phox, p67phox and Nox-4), myocardial apoptotic markers and endoplasmic reticulum stress markers in comparison to those of normal and all these effects are expectedly down-regulated by an olmesartan. In addition, attenuated protein levels of phosphatidylinositol-3-kinase (PI3K) and phospho-Akt in the vehicle-treated EAM rats were prevented by olmesartan treatment. Our results suggest that beneficial effects of olmesartan treatment was more effective therapy in combating the inflammation, oxidative stress, apoptosis and signaling pathways associated with heart failure at least in part via the modulation of ANG 1-7 mas receptor.

AB - Angiotensin-converting enzyme 2 (ACE-2) is a membrane-associated carboxy-peptidase catalyzes the conversion of the vasoconstrictor angiotensin (ANG)-II to the vasodilatory peptide ANG 1-7. In view of the expanding axis of the renin angiotensin system, we have investigated the cardioprotective effects of olmesartan (10. mg/kg/day) in experimental autoimmune myocarditis. Olmesartan treatment effectively suppressed the myocardial protein expressions of inflammatory markers in comparison to the vehicle-treated rats. However, the protein and mRNA levels of ACE-2 and ANG 1-7, and its receptor Mas were upregulated in olmesartan treated group compared to vehicle-treated rats. Olmesartan medoxomil treatment significantly decreased the expression levels of phospho-p38 mitogen-activated protein kinase (MAPK), phospho-JNK, phospho-ERK and phospho-(MAPK) activated protein kinase-2 than with those of vehicle-treated rats. Moreover, vehicle-treated rats were shown to be up-regulated protein expressions of NADPH oxidase subunits (p47phox, p67phox and Nox-4), myocardial apoptotic markers and endoplasmic reticulum stress markers in comparison to those of normal and all these effects are expectedly down-regulated by an olmesartan. In addition, attenuated protein levels of phosphatidylinositol-3-kinase (PI3K) and phospho-Akt in the vehicle-treated EAM rats were prevented by olmesartan treatment. Our results suggest that beneficial effects of olmesartan treatment was more effective therapy in combating the inflammation, oxidative stress, apoptosis and signaling pathways associated with heart failure at least in part via the modulation of ANG 1-7 mas receptor.

KW - Angiotensin 1-7

KW - Angiotensin-converting enzyme-2

KW - Angiotensin-II

KW - Experimental autoimmune myocarditis

KW - MAPK signaling pathways

KW - Olmesartan

UR - http://www.scopus.com/inward/record.url?scp=84862777926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862777926&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2011.12.010

DO - 10.1016/j.mce.2011.12.010

M3 - Article

C2 - 22200414

AN - SCOPUS:84862777926

VL - 351

SP - 208

EP - 219

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 2

ER -